australian healthcare

We believe lacklustre revenue growth and lumpy profitability mask the potential of SDI Limited’s post-COVID strategic shift

There is much more to come from Neuren. Following two years of substantial progress, we see significant upside from current levels.

There are only two states in software according to Pro Medicus CEO Dr Sam Hupert: "quick or dead". And Hupert doesn't much care to be dead.

Today's share price action certainly would suggest so.

Just because CSL hadn’t factored in financial benefit from CSL112, it doesn’t mean the market hadn’t.

The -32% decline in the share price of Australia's number three Large Cap has brought out the biases and prejudices in all of us

Rising bond yields and higher interest rate expectations has not been a good backdrop for stocks, but these three stocks are positive.

Morgan Stanley released its Post-result and FY24 Outlook for Australian Healthcare with a number of changes.

Profits may be up at Ramsay Health Care but the final dividend dropped by nearly 50%. In this interview, CEO Craig McNally shares why.

IML's Hugh Giddy bought more of this stock a little over a year ago, and he has no intentions of selling after today's results.

Wilson Asset Management's Anna Milne says today's results indicate the healthcare giant continues to be positioned for strong growth.

Small and micro-cap companies are notoriously volatile, but NovaPort Capital's Sinclair Currie argues a focus on quality is key to success.

Against a challenging economic backdrop, the Healthcare sector is well placed to deliver earnings growth in the coming years.

CSL shares have tracked sideways in recent years but is this a cause for concern? We dig into the topic with Alphinity’s Stuart Welch.

Several Alternatives spheres offer appealing potential despite persistent macro and market volatility, explains WAM Alternative Assets' Dania Zinurova.

Are healthcare stocks "expensive defensives"? And what do brokers, and Wilson Asset Management's Anna Milne, think of the biggest ASX companies in the sector? We find...

Sean, Alan, Dan and the Australian Eagle team, now running The Montgomery Fund, and The Montgomery Fund alongside me as co-PM, have held quality healthcare...

Healthcare is a tough space in which to win. With high barriers to entry and many problems to solve, finding and dominating your niche can be one of the many...

Profits down might normally be a disappointing result for any company. But in the case of Australia’s best-loved healthcare giant, it looks like a temporary case of...

There has been a flight to quality amid the recent market volatility, with investors scouring the market for companies with sustainable earnings. This biotech has...